Humira Cleared For Additional Psoriatic Arthritis Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Broadened indication for inhibiting structural joint damage matches Enbrel and Remicade indications.
You may also be interested in...
Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease
Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.
Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease
Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.
NICE Says Sequential Use Of TNF Inhibitors To Treat RA Is Not Cost Effective
The agency, however, recommends use of Abbott's Humira, Wyeth's Enbrel and Johnson & Johnson's Remicade to treat RA.